TERA Exposure and Hypertension: Evidence-Based Relationship and Management
Veterans with deployment-related toxic exposures have significantly increased risk of hypertension and should be screened using standard blood pressure protocols per VA/DoD guidelines, with particular attention to those exposed to burn pits, herbicides, and chemical/biological agents.
The Link Between Toxic Exposures and Hypertension
Documented Associations
Multiple studies demonstrate clear associations between military toxic exposures and hypertension risk:
Burn pit exposure: For every 100 days of deployment to bases with open burn pits, veterans experienced a 2% increased odds of hypertension (aOR 1.02,95% CI 1.02-1.03) 1. This represents a dose-dependent relationship where longer exposures confer greater risk.
Chemical/biological agents: Exposure for 7-30 days was associated with over 4-fold increased odds of hypertension (OR 4.18,95% CI 1.48-11.86) 2. Longer exposures (31+ days) were associated with atherosclerotic cardiovascular disease (OR 4.24,95% CI 1.20-14.94).
Gulf War Illness (GWI): Veterans with GWI had 67% higher odds of self-reported hypertension (aOR 1.67,95% CI 1.18-2.36) and nearly 3-fold higher odds of documented hypertension in electronic health records (aOR 2.84,95% CI 1.92-4.20) 3.
Herbicide exposure: Vietnam-era Army Chemical Corps veterans who sprayed herbicides had 74% increased odds of hypertension (aOR 1.74,95% CI 1.44-2.11), with the highest risk in Vietnam-service sprayers versus non-Vietnam non-sprayers (aOR 2.21,95% CI 1.76-2.77) 4.
Mechanistic Considerations
The relationship appears mediated through multiple pathways including metabolic dysregulation, lipid abnormalities, and autonomic dysfunction. Importantly, toxic exposures were associated with worsening health trajectories over time, with greater increases in chronic disease diagnoses over 10-year follow-up 5.
Screening Approach
Blood Pressure Measurement Protocol
Follow the 2020 VA/DoD hypertension guideline standards 6:
- Routine screening is essential given the asymptomatic nature of hypertension and high rates of undiagnosed disease (up to 33% in younger veterans aged 20-44 years)
- Use proper technique with appropriate cuff size, patient seated with back supported, feet flat on floor, arm at heart level
- Obtain multiple measurements on separate occasions before diagnosis
- Consider out-of-office BP monitoring (home or ambulatory) to confirm diagnosis and rule out white coat hypertension
Risk Stratification for Veterans
Document specific exposure history:
- Duration and location of deployment to bases with burn pits
- Exposure to oil well fire smoke (particularly 7-30 days or longer)
- Chemical/biological agent exposure
- Herbicide/pesticide exposure
- Pyridostigmine bromide pill use
Screen for Gulf War Illness criteria in 1990-1991 Gulf War veterans, as GWI independently predicts hypertension risk beyond combat exposure 3.
Diagnostic Thresholds
The 2020 VA/DoD guideline uses SBP ≥140 mm Hg or DBP ≥90 mm Hg as the diagnostic threshold 6, which differs from the 2017 ACC/AHA threshold of 130/80 mm Hg. However, the 2025 ACC/AHA guideline should be consulted for the most current recommendations 7, 8.
Management Strategy
Treatment Goals
Target BP should be individualized based on:
- Age and comorbidities
- Presence of target organ damage (left ventricular hypertrophy, CKD, cerebrovascular disease)
- Diabetes status (>80% of T2D patients have hypertension) 7
Pharmacologic Approach
For veterans with CKD and albuminuria (common with toxic exposures):
- First-line: ACE inhibitor or ARB for those with eGFR <60 mL/min/1.73 m² and moderate-to-severe albuminuria (≥30 mg/g) 7
- Expect an initial eGFR decline up to 30% with RAAS inhibitors—this is protective long-term and should not prompt discontinuation unless decline exceeds 30% 7
- Monitor eGFR 2-4 weeks after initiation or dose changes
- Consider nephrology referral if persistent decline >30% or concern for renal artery stenosis
For veterans with diabetes:
- ACE inhibitor or ARB remains first-line
- SGLT2 inhibitors and GLP-1 receptor agonists provide additional kidney protection and modest BP benefits 7
Monitoring for Complications
Screen for hypertension-related target organ damage:
- Cardiovascular: ECG for left ventricular hypertrophy, assess for heart failure symptoms
- Renal: eGFR and urine albumin-to-creatinine ratio
- Cerebrovascular: cognitive screening, history of stroke/TIA
- Retinal: fundoscopic examination if indicated
Common pitfall: Over 50% of individuals with hypertension develop at least one form of target organ damage longitudinally 7. The number of affected organs correlates with CVD risk, making comprehensive screening essential.
Nonpharmacologic Interventions
Per VA/DoD guidelines, emphasize:
- Sodium restriction
- Weight management (particularly important given metabolic dysregulation from toxic exposures)
- Physical activity
- Alcohol moderation
- Smoking cessation
Key Clinical Caveats
Toxic exposures represent population-specific risk enhancers that should be considered in individualized clinical risk assessment 2. Document exposure history in the medical record.
The association between toxic exposures and hypertension persists after adjusting for traditional risk factors 2, 3, suggesting a direct pathophysiologic mechanism rather than confounding.
Mental health comorbidity is common: Toxic exposures are associated with worsening mental health symptoms over time 5. Screen for and address PTSD, depression, and anxiety as part of comprehensive care.
Longitudinal monitoring is critical: Veterans with toxic exposures show progressive worsening of both physical and mental health over decades 5, requiring sustained engagement in care.
Electrolyte monitoring: When using RAAS inhibitors, monitor potassium and consider potassium-lowering binders (patiromer, sodium zirconium cyclosilicate) if hyperkalemia develops, rather than discontinuing protective therapy 7.